EP2203114B1 - Medizinische messvorrichtung zur bioelektrischen impedanzmessung - Google Patents
Medizinische messvorrichtung zur bioelektrischen impedanzmessung Download PDFInfo
- Publication number
- EP2203114B1 EP2203114B1 EP08801910A EP08801910A EP2203114B1 EP 2203114 B1 EP2203114 B1 EP 2203114B1 EP 08801910 A EP08801910 A EP 08801910A EP 08801910 A EP08801910 A EP 08801910A EP 2203114 B1 EP2203114 B1 EP 2203114B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- measurement
- unit
- radiation
- electrodes
- measurement device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002847 impedance measurement Methods 0.000 title claims abstract description 31
- 238000005259 measurement Methods 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000008569 process Effects 0.000 claims abstract description 4
- 230000005855 radiation Effects 0.000 claims description 78
- 238000011156 evaluation Methods 0.000 claims description 36
- 230000003287 optical effect Effects 0.000 claims description 23
- 230000010412 perfusion Effects 0.000 claims description 6
- 238000004891 communication Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 230000036760 body temperature Effects 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 description 44
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 36
- 239000008103 glucose Substances 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 229910052760 oxygen Inorganic materials 0.000 description 19
- 239000001301 oxygen Substances 0.000 description 19
- 230000036284 oxygen consumption Effects 0.000 description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 13
- 230000004060 metabolic process Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000003925 fat Substances 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 235000012631 food intake Nutrition 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 6
- 108010064719 Oxyhemoglobins Proteins 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 210000003722 extracellular fluid Anatomy 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000012806 monitoring device Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108010014173 Factor X Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000013307 optical fiber Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011871 bio-impedance analysis Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002496 oximetry Methods 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000002106 pulse oximetry Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 206010006578 Bundle-Branch Block Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- 206010040738 Sinus arrest Diseases 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001171 adenosinetriphosphoric effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/332—Portable devices specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0537—Measuring body composition by impedance, e.g. tissue hydration or fat content
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14552—Details of sensors specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6825—Hand
- A61B5/6826—Finger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/683—Means for maintaining contact with the body
- A61B5/6838—Clamps or clips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6887—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient mounted on external non-worn devices, e.g. non-medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7253—Details of waveform analysis characterised by using transforms
- A61B5/7257—Details of waveform analysis characterised by using transforms using Fourier transforms
Definitions
- the invention relates to a medical measuring device with an impedance measuring unit for detecting an impedance measuring signal from the skin surface of a patient to be examined via at least one measuring electrode pair.
- bioelectrical impedance methods are used in the determination of nutritional status in both healthy and sick people.
- the direct measurement of body composition is currently only possible in research facilities by weighing the patient under water. So-called hydrostatic weighing makes use of the fact that fat, muscles, bones, body fluids and other parts of the body have different specific densities. Since this method of measurement is very time-consuming and unpleasant for the patient, other indirect methods for determining body composition are often used.
- a widely used indirect method is the measurement of the bioelectrical impedance of the body. This technique exploits the fact that the impedance of the human body is related to the different conductivities within the body. If a constant alternating current of small amplitude is applied in biological structures, then a frequency-dependent impedance can be measured.
- the human body consists of intra- and extracellular fluid, which can be considered electrical conductors, and cell membranes, which have a capacitive character.
- intra- and extracellular fluid which can be considered electrical conductors, and cell membranes, which have a capacitive character.
- the flow of current is mainly due to the extracellular fluid, because the cell membranes due to their capacitive Character act as a capacitor.
- the current is also conducted across the cell membranes and the intercellular fluid. In the region of high frequencies, the current flow thus occurs both ohmically by the extracellular fluid and capacitively by the cell membranes and the intercellular fluid.
- the resulting, measurable AC resistor thus has an ohmic R (resistance) and a capacitive X c share (reactance) component, and is referred to the measurement of the bioelectrical impedance Z.
- R resistance
- X c share capacitive X c share
- This global index is the result of the integral measurement method used in these techniques: Typically, the electrodes are connected to both hands (determining the upper body global index), or a measurement is made between a hand and a foot (global index for the measured body side).
- the invention has for its object to provide an advanced measuring device for bioelectrical impedance measurement.
- the measuring device is based on a further development of the established techniques in the direction of local bioelectrical impedance measurement. Shortening the electrode gap to within a range of less than one millimeter to a few centimeters does not integrate over the entire body, but locally absorbs the bioelectrical impedance. According to the invention, all the electrodes touch one and the same local area of the skin surface, i.e. all electrodes with the same body part (for example hand, finger, foot or toe) are touched by the patient to be examined.
- the measuring device for measuring the local resistance and reactance expediently has a feed electrode pair for impressing an alternating current of variable frequency across the skin surface into the body tissue of the patient to be examined, namely in the area of the skin surface contacting the measuring electrodes.
- the distance of the feed electrodes corresponding to the measuring electrodes is a few millimeters to a few centimeters.
- An embodiment in which the measuring and feeding electrodes are designed as contact strips running parallel to one another has proved to be particularly advantageous. This makes it possible to reduce the local impedance of body tissue without distorting influences, e.g. due to the contact resistance between the electrodes and the skin surface.
- the measuring device expediently has an alternating current generator.
- the impedance measurement signal is digitized by an analog-to-digital converter and then subjected to a discrete Fourier transform (DFT).
- the DFT algorithm then provides the real and imaginary parts of the impedance, ie, the resistance and reactance values. These values can be further processed digitally for evaluation.
- the electrode spacing is up to a maximum of 10 cm, more preferably 50 microns to 5 cm, more preferably 100 microns to 1 cm, most preferably 1 mm to 5 mm.
- the measuring device expediently has an evaluation unit connected to the impedance measuring unit.
- the evaluation unit may be program-controlled, so that the evaluation of the impedance measurement signals can be implemented flexibly by software.
- the local bioimpedance changes due to the changing amount of blood within a pulse beat, whereby a determination of the heart rate over the local bioelectrical impedance is possible.
- the pulse amplitude is determined as an important physiological parameter. It has been shown that this pulse amplitude correlates with the body temperature, ie it is possible to determine the temperature of the examined body site with the aid of the bioimpedance analysis.
- the local bioimpedance depends on the amount of fluid, ie on the local blood quantity in the examined tissue, which makes it possible to determine the local perfusion (the circulatory local volume fluctuation, eg in the form of a volume pulse signal) of the examined tissue.
- the local bioelectrical impedance of the body changes as a function of food intake, so that the bioimpedance can be used to examine the metabolism, which is known to be determined by the blood glucose level.
- the measuring device according to the invention thus enables non-invasive monitoring of the blood glucose value, the effect of glucose or the energy requirement of the glucose-initiated physiological reactions in the body being investigated.
- a suitable algorithm which is implemented by software in the evaluation unit, it is possible to make statements about the blood glucose level from the recorded impedance measurement signals.
- a particularly useful embodiment of the measuring device according to the invention results from a combination with further measuring modalities.
- the measuring device can additionally be equipped with an optical measuring unit.
- This has a radiation source for irradiating the examined body tissue with electromagnetic radiation, and at least one radiation sensor for detecting the radiation scattered and / or transmitted by the body tissue.
- a radiation source conventional light-emitting diodes or laser diodes in question
- the optical radiation i. Emit light in the corresponding spectral range. It has proven to be particularly advantageous if the device according to the invention measures the radiation absorption in the examined body tissue at at least two or better three different wavelengths of light, in order to determine the oxygen concentration of the blood and the perfusion of the tissue.
- the optical measuring unit thus forms a pulse oximetry unit of the measuring device according to the invention.
- the optical measuring unit of the measuring device comprises at least two radiation sensors for detecting the radiation scattered and / or transmitted by the body tissue, the radiation sensors being arranged at different distances from the radiation source.
- the radiation sensors being arranged at different distances from the radiation source.
- an embodiment of the measuring device according to the invention in which at least two radiation sources are provided, which are different volume regions of the examined body tissue irradiate.
- the determination of the variable oxygen consumption in turn allows conclusions about the local energy consumption, which is directly correlated with the oxygen consumption. It is particularly interesting that this in turn allows conclusions about the glucose level.
- the measuring device according to the invention advantageously also allows a non-invasive determination of the blood glucose level by optical measurement.
- the redundant determination of the blood glucose level by means of the various measurement modalities increases the accuracy and reliability of the measuring device according to the invention.
- the two radiation sources of the optical measuring unit of the measuring device according to the invention should be designed in such a way that the volume ranges irradiated by them in each case are affected differently with respect to the blood circulation with oxygen-poor or oxygen-rich blood.
- a light emitting diode and a laser having similar wavelengths eg, 630 nm and 650 nm
- the two radiation sources differ by the opening angle of the radiation. While z. B.
- the LED irradiates the LED at a large opening angle in the body tissue examined, the light of the laser diode enters at a very small opening angle in the body tissue. This has the consequence that with the two radiation sources different volume areas of the body tissue are detected. Due to the large opening angle, the LED detects a larger volume area of the non-perfused epidermis than the laser. The perfused epidermis is virtually unaffected by a change in hemoglobin concentration. Accordingly, the intensity of the light emitted by the body tissue and / or transmitted radiation of the light emitting diode is less dependent on a change in the hemoglobin concentration than the intensity the radiation of the laser.
- the prerequisite is that the wavelength of the radiation emitted by the two radiation sources is selected such that the radiation is absorbed to a different extent by oxyhemoglobin or desoxihemoglobin.
- the wavelength should therefore be between 600 and 700 nm, preferably between 630 and 650 nm.
- the at least one radiation source is provided with a light-conducting element, e.g. connected to an optical fiber.
- the radiation emitted by the radiation source or the radiation sources is conducted to the skin surface of the patient to be examined via the light-conducting element.
- the different radiation sources can be coupled in different ways to the light-conducting element. In this way, a different radiation characteristic of the radiation of the various sources in the body tissue to be examined can be achieved.
- the evaluation unit of the measuring device according to the invention can also be advantageously used for the evaluation of the optical measuring signals.
- the evaluation unit is expediently designed to determine a local metabolic parameter from the radiation of the two radiation sources scattered and / or transmitted by the body tissue.
- oxygen is consumed in the body tissue examined, oxyhemoglobin is converted to desoxihemoglobin.
- the evaluation unit of the measuring device according to the invention is usefully set up for determining the local oxygen consumption and / or the blood glucose level on the basis of the intensities of the radiation of the two radiation sources scattered and / or transmitted by the body tissue.
- an ECG unit for detecting an ECG signal via two or more ECG electrodes By an ECG unit for detecting an ECG signal via two or more ECG electrodes, the functional scope of the measuring device according to the invention is advantageously extended. According to this advantageous development of the invention, by means of the measuring device e.g. Impedance measurement signals, pulse oximetry signals and ECG signals combined recorded and evaluated.
- the evaluation unit of the measuring device can then be set up with advantage for evaluating the chronological progression of the volume pulse signals and the ECG signals.
- the evaluation unit of the measuring device according to the invention is capable of automatically detecting the R-waves in the ECG signal. This automatically determines the exact time of the heartbeat.
- the evaluation unit is able to recognize the maxima in the volume pulse signal. Based on the maxima in the volume pulse signal, the time of arrival of a pulse wave triggered in the case of a heartbeat can be detected at the peripheral measuring location detected by the measuring device. Thus, finally, the time interval between an R-wave in the ECG signal and the subsequent maximum in the volume pulse signal can be determined.
- This time interval is a measure of the so-called pulse wave velocity.
- a statement about the blood pressure can be made on the basis of the pulse wave velocity.
- a shortening of the pulse wave velocity is in fact accompanied by an increase in blood pressure, while an extension of the pulse wave velocity suggests a reduction in blood pressure.
- the pulse wave velocity is dependent on the density of the blood and in particular on the elasticity of the blood vessel walls (for example the aorta). From the elasticity of the blood vessels can in turn be concluded that arteriosclerosis may be present.
- the evaluation of the measurement signals may also include the absolute values of the heart rate, the heart rate variability and corresponding arrhythmias of the heart.
- arrhythmias such as sinus tachycardia, sinus bradycardia, sinus arrest and so-called escape beats can be detected automatically.
- the ECG signal can also statements about the duration of the atrial contraction of the heart at a Heartbeat, the duration of the ventricular contraction and the duration of relaxation of the ventricle, etc. are determined.
- preliminary diagnoses are possible with respect to so-called blocks in the conduction of cardiac electrical stimulation signals (AV block, bundle branch block, etc.) and also with regard to circulatory disorders or infarcts. Further irregularities in the pulse progression can be determined by means of the volume pulse signal. It makes sense to use at least one of the ECG electrodes of the measuring device according to the invention simultaneously as a feed or measuring electrode of the impedance measuring unit.
- the measuring device comprises an integrated temperature or heat sensor.
- This can be used to determine local heat production.
- the temperature sensor is designed to measure the surface temperature of the skin at the measuring location. Based on the heat exchange can be deduced the local metabolic activity.
- the heat sensor is suitable for determining local perfusion.
- the inventive combination of the aforementioned measuring methods namely the impedance measurement, the oximetry, the ECG measurement and the temperature or heat measurement.
- the evaluation unit of the measuring device By means of the evaluation unit of the measuring device, all measuring signals can be evaluated and combined by a suitable algorithm in order to examine the metabolism.
- a high level of effectiveness and redundancy and thus reliability in the detection of pathological changes is achieved.
- the response of the metabolism of the human body to food intake is characteristically dependent on the composition of the diet.
- the body's vascular system responds depending on how much energy the body needs to digest the food it is eating.
- the evaluation unit of the measuring device according to the invention for evaluating the time course of the pulse wave velocity and determining the composition of a user of the measuring device food is expediently set up based on the time course of the pulse wave velocity from the time of food intake.
- the pulse wave velocity, as well as the blood pressure amplitude and the pulse change as soon as food intake begins.
- the maxima and the The respective time points of the maxima are influenced by the food composition.
- the course and the absolute height of pulse wave velocity, blood pressure amplitude and pulse can be used to determine the composition of the ingested food by means of the evaluation unit of the measuring device according to the invention.
- the metabolism of the human body is in the normal state, ie at rest and in the so-called thermoneutral zone, essentially determined by the glucose balance. Therefore, the glucose concentration in the cells of the body tissue in this normal state can be described as a pure function of the heat production and the oxygen consumption.
- Glu f 1 .DELTA.T . V ⁇ O 2 .
- [Glu] stands for the glucose concentration.
- f 1 ( ⁇ T, VO 2 ) indicates the functional dependence of the glucose concentration on the heat production and the oxygen consumption.
- the oxygen consumption results, as described above, from the difference between venous and arterial oxygen saturation and the blood circulation.
- X is a factor that is negative after food intake. X depends on the composition of the food consumed. In particular, X depends on the ratio of fat and carbohydrates involved in metabolism. The factor X can be determined as described above on the basis of the time course of the pulse wave velocity. X is 0, if pure carbohydrates or glucose are consumed directly. The amount of X increases as the proportion of fat in the food consumed increases.
- f 2 ( ⁇ T, VO 2 ) indicates the functional dependence of the glucose concentration on the heat production and the oxygen consumption for the fat metabolism.
- the evaluation unit of the measuring device according to the invention can thus be set up to determine the local glucose concentration from the local oxygen consumption and the local heat production.
- the measuring device must have the appropriate measurement modalities.
- the determination of the oxygen consumption can, as explained above, be effected by the combination of the oximetry with the bioelectrical impedance measurement.
- a suitable heat sensor is then additionally required.
- the correction factor X for example from the time profile of the pulse wave velocity, should be determined. This can, as also explained above, be carried out by combined measurement of ECG signals and pulse oximetric signals.
- a bioelectrical impedance measuring unit, a pulse oximeter, an ECG unit and a heat sensor are thus advantageously combined in the measuring device according to the invention.
- the constants a, b and c depend on the individual physiology of the user of the measuring device.
- the evaluation unit of the Measuring device according to the invention should also be set up to determine the blood glucose level from the local glucose concentration, whereby parameters dependent on the physiology of the user of the measuring device must be taken into account. These parameters can be determined by appropriate calibration, for example by comparison with conventionally invasively determined blood glucose values.
- measuring modalities of the measuring device according to the invention with a low-pass filter and / or a 50/60 Hz filter for the purpose of freeing superimposed electromagnetic interference.
- a suitable electronic circuit for example before the analog / digital conversion
- the measurement data processing by means of the evaluation unit.
- the measuring device in which all measurement modalities are combined to form a compact sensor unit, in such a way that all measurements are made in the same area the skin surface of the patient to be examined.
- a compact sensor unit is created, which provides a variety of diagnostic measurements. These can be evaluated individually or in combination to quickly and reliably obtain meaningful information about the health of the patient being examined.
- the compact sensor unit can be prefabricated as a fully functional part cost in large numbers and integrated into diagnostic equipment of various kinds. The actual measurement can be carried out particularly easily and conveniently.
- the surface of the sensor housing where eg the electrodes of the impedance measuring unit and the ECG unit are located, is brought into contact with the skin in the area of the body tissue to be examined. This can be done for example by simply placing a finger of the patient on the housing surface of the sensor unit. The impedance measurement and the ECG derivation are then carried out simultaneously via the skin site touching the sensor unit.
- the measuring device can be integrated into a mobile monitoring device, in which the above-mentioned medical measuring modalities individually or in combination form the data recording unit for measuring data recording and in which the program-controlled evaluation unit is provided for evaluating the recorded measurement data.
- a memory unit serves to store the recorded and / or the calculated / evaluated data.
- a display unit is provided for visualizing the recorded and / or evaluated data.
- a data transmission unit is used to transmit the recorded data and / or the calculated / evaluated data to external devices. This can be a conventional wired or even a wireless interface (for example, according to the Bluetooth standard).
- the data stored in the memory unit of the monitoring device can be read out by a treating physician and evaluated in order to monitor the course of treatments of the patient.
- the data transmission interface of the monitoring device can be used to transmit the data stored in the storage unit of the monitoring device data to a personal computer of the doctor. It is expediently also possible to carry out remote data transmission of the diagnostic data recorded and evaluated by means of the sensor unit.
- the data transmission can take place eg via a data network (Internet).
- the diagnostic data can be transmitted over a mobile network.
- the raw measurement signals or the evaluated diagnostic data may, for example, be transmitted to a central office ("Healthcare Center") for further analysis and documentation as well as for monitoring the time evolution of individual values.
- Healthcare Center central office
- the data are evaluated, for example, by means of suitable analysis algorithms, possibly taking account of stored patient data (including information relating to chronic diseases or previous illnesses).
- the result can in turn be sent back via the respective data or communication network in order to inform the user of the measuring device accordingly about his state of health.
- From the central location it is also possible, if required, to initiate further targeted measurements by means of the sensor unit according to the invention.
- queries to the patient via the data or communication network be transmitted. If indications of a medical emergency arise from the measurement and evaluation results, the necessary measures (eg automatic alerting of the rescue service) can be initiated immediately.
- Another advantage of the remote data transmission is that the required software for evaluating the measurement signals need not be implemented in the device itself, but only at the central location where the data is received, maintained and maintained.
- the data acquisition unit (the impedance measuring unit), the evaluation unit, the memory unit, the display unit and the transmission unit are accommodated in a common housing.
- the measuring device may be a self-contained device, or may be integrated into an otherwise usable electronic device (e.g., wristwatch, mobile phone, MP3 player, digital camera).
- any entertainment or communication technology device e.g. Desktop, notebook, laptop, mobile phone, palmtop or handheld. The user of such a device can quickly, conveniently and inconspicuously carry out a measurement at any time to acquire the physiological parameters of interest.
- a fixing device for fixing a body part, for example a finger, of the patient to be examined.
- the contact pressure of the body tissue (eg the finger) on the optical sensor or on the measuring and supply electrodes of the impedance measuring unit has a significant influence on the measuring signals. Consequently, it may be useful to provide by means of the fixing device for a defined contact pressure.
- the Fixing device may include, for example, an inflatable air cushion, which (soft) presses the corresponding body part against the measuring and / or feeding electrodes or against the optical sensors and fixed there. By fixing advantageous movements of the body part are prevented, which could distort the measurement result.
- a plurality of feeding and / or measuring electrodes is arranged in the form of a matrix. This makes it possible to produce different spatial configurations in AC supply and voltage measurement. The additional information thus obtained makes it possible to draw conclusions about the pH, the pCO 2 value, the pO 2 value and the electrolyte balance (Na + , K + , Ca 2+ , Mg 2 ++ concentration etc.).
- the illustrated bioelectrical impedance measuring unit 100 of the measuring device comprises two electrodes 1 for supplying electrical alternating current of the variable frequency current source 2 and two or more measuring electrodes 3 for impedance measurement of the body tissue 200 in the area of the finger of the user of the device for determining the local resistance and the local reactance. Due to the four-point measurement, contact resistances between the electrodes 1, 3 and the body tissue 200 do not falsify the measurement. It makes sense that the distance between the electrodes 1, 3 is only a few millimeters to a few centimeters. During the measuring process, all four electrodes 1, 3 for the local detection of the impedance measurement signal simultaneously touch the same area of the skin surface on the user's finger.
- the current source 2 By means of the current source 2, an alternating current of variable frequency is generated. In this way the measurement of the complex impedance is possible.
- the measuring signal is detected by means of a voltmeter 4. It makes sense to use the measuring signal by means of a (in the FIG. 1 not shown) digitized analog and digital converter and then subjected to a discrete Fourier transform (DFT).
- the DFT algorithm then provides the real and imaginary parts of the impedance, ie, the resistance and reactance values.
- the illustrated impedance measuring unit 100 may, due to the small electrode spacing, be constructed very compact and thus well integrated into a mobile electronic device (eg wristwatch, mobile phone, MP3 player, digital camera, handheld, etc.).
- the FIG. 2 shows the generally designated 300 measuring device according to the invention as a compact sensor unit, which can be integrated into any device.
- the measuring device 300 has various measuring modalities that are accessible on the surface of a sensor housing 400.
- the dimensions of the sensor housing 400 are, for example, only 10 x 7 x 3 mm. This touches the user of the measuring device 300 to perform a measurement, for example with the fingertips.
- light sources 5, 5 ' are integrated, for example in the form of light-emitting diodes, which is capable of emitting light at different wavelengths.
- the measuring device 300 comprises one or more photosensors 6.
- the photosensors are arranged in the immediate vicinity of the light source 5 or 5 '.
- the sensors 6 receive the light of the light source 5 or 5 'scattered in the tissue at the user's fingertip.
- a heat sensor 7 is provided immediately adjacent to the light source 5 or 5 '. This ensures that the heat measurement takes place at the same measuring location as the optical measurement.
- a total of four electrodes 1 and 3 for measuring the bioelectrical impedance are provided on the surface of the measuring device 300.
- the electrodes 1, 3 are separated from each other by insulating strips 8. The user of the device simultaneously touches the four electrodes, ie the measuring and feeding electrodes, with one hand, as described above with respect to FIGS FIG. 1 explained.
- At least one of the electrodes designated by the reference numeral 1 is also used as an ECG electrode of an ECG unit likewise integrated into the measuring device 300.
- Another ECG electrode (counter electrode, not shown) is located elsewhere, so that the electrodes can be touched with the fingertips. This results in a two-point derivation (arm-to-arm measurement).
- the radiation source 5 is a light-emitting diode
- the radiation source 5 ' is a laser, for example a so-called vertical cavity surface-emitting laser (VCSEL).
- VCSEL vertical cavity surface-emitting laser
- the wavelength of the radiation emitted by the two radiation sources 5 and 5 'in each case must be in a range in which the light of oxyhemoglobin and desoxihemoglobin is absorbed to different degrees.
- further radiation sources in the FIG. 2 not shown) whose light wavelength is in a spectral range in which the light absorption of oxyhemoglobin and desoxihemoglobin is substantially the same (so-called isobatic point).
- the light emitted by the light emitting diode or by the laser light can be guided by means of appropriate optical fibers to the appropriate location on the housing surface of the keyboard.
- the reference numerals 5 and 5 'in the FIG. 1 the corresponding fiber ends are shown. It is possible to couple the light-emitting diode and the laser to the corresponding fibers in such a way that they radiate into the body tissue to be examined at the desired different opening angle. Accordingly, different volumes of body tissue are examined with both radiation sources. Due to the larger opening angle, the proportion of non-perfused epidermis on the body tissue examined by means of the light-emitting diode is greater than in the case of the laser.
- the scattered in the body tissue and partially absorbed light of both the radiation source 5 and the radiation source 5 ' is detected by means of the sensors 6.
- the sensors 6 need not be arranged directly on the surface of the housing 400. Instead, the light can be supplied via optical fibers to the sensors arranged in the interior of the measuring device 300.
- the two light sources 5 and 5' can be operated differently modulated in time, the signals detected by the sensors 6 being correspondingly demodulated. Alternatively, it is possible to distinguish the radiation of the two radiation sources 5 and 5 'based on the different wavelength.
- the radiation intensity of the radiation emitted by the radiation sources 5 and 5 ' is weakened with the path length when passing through the body tissue, whereby the relationship of the intensity attenuation with the concentration of the absorbing substance (oxygenated hemoglobin) is given by the known Lambert-Beer law.
- the interest parameters of the intensity attenuation are determined, and separately for each of the radiation sources 5 and 5 'detected volume ranges of the examined body tissue.
- the parameters of the intensity attenuation attributable to the different radiation sources 5 and 5 ' can be related to one another by means of a suitably program-controlled evaluation unit in order to carry out a differential measurement in this way.
- quotients are calculated from the parameters of the intensity attenuation of the radiation of the two radiation sources 5 and 5 '. Changes in these quotients can then be used to deduce changes in metabolism. If, for example, the blood glucose level rises after ingestion, a correspondingly higher amount of glucose reaches the cells of the body tissue and is metabolized there (after a certain time delay). This oxygen is consumed. The cells receive this oxygen via the blood. In this case, the deoxygenated hemoglobin becomes deoxygenated hemoglobin by the release of oxygen. Accordingly, the ratio of deoxygenated hemoglobin to oxygenated increases.
- the changes in the hemoglobin concentration have a different effect on the respective intensity attenuation.
- changes in the hemoglobin concentration can be detected from the quotients of intensity attenuation parameters.
- This makes it possible to indirectly deduce the oxygen consumption.
- the oxygen consumption in turn depends on the blood glucose level
- the blood glucose level can also be determined by means of the illustrated differential measurement of the radiation absorption.
- the bioimpedance analysis is carried out via the electrodes 1, 3. The purpose of the bioimpedance measurement is above all the determination of the local perfusion. This is used as a further parameter in the determination of the oxygen consumption and thus also of the blood glucose level.
- Different opening angles of the radiation can also be generated with only one radiation source 5 by using corresponding optical elements (eg, beam splitters, lenses, etc.).
- FIG. 3 shows an alternative embodiment of the measuring device 300 according to the invention with concentrically arranged, substantially Circular electrodes 1, 3.
- the arrangement according to FIG. 2 or the one according to FIG. 3 more suitable.
- FIG. 4 schematically shows the structure of the measuring device 300 according to the invention as a block diagram.
- Measuring device 300 comprises an optical measuring unit 130 for the optical measurement of the oxygen concentration in the blood vessel system of the body tissue at the respective measuring location.
- the pulse oximetric signals detected by means of the optical measuring unit 130 are supplied to an analysis unit 110.
- Another essential component of the measuring device 300 is a heat measuring unit 120 for determining the local heat production.
- the heat measurement unit 120 is a special heat sensor which isolates the body site being examined. This site can thus only absorb or release heat through the bloodstream. Therefore, it is possible to determine the blood circulation and the heat production by the time-resolved measurement of the temperature. In the case of a strong circulation, the examined body site reaches its maximum temperature in a very short time.
- measuring device 300 includes impedance measuring unit 100, which serves to detect local tissue parameters by bioelectrical impedance measurement.
- the measurement signals of the impedance measurement unit 100 are also processed by the analysis unit 110.
- an ECG unit 132 is provided for detecting an ECG signal.
- the ECG unit 132 is also connected to the analysis unit 110 for processing the ECG signals.
- the heat measuring unit 120 is connected to the thermal sensor 7.
- the impedance measurement unit 100 acquires measurement signals via the electrodes 1 and 3, respectively, of the measurement device 300.
- the analysis unit 110 carries out preprocessing of all measurement signals. For this purpose, the signals pass through a bandpass filter, to filter out disturbances in the range of the mains frequency of 50 or 60 Hz. Furthermore, the signals are subjected to noise suppression. After passing through the analysis unit 110, the processed signals of the optical measuring unit 130, the heat measuring unit 120, the impedance measuring unit 100 and the ECG unit 132 reach an evaluation unit 140.
- the evaluation unit 140 is responsible for determining the parameters which are essential for the diagnosis from the measuring signals to calculate. The functions of the evaluation unit 140 are essentially realized by software.
- the composition of the body tissue examined (water content, fat content, etc.) is calculated.
- the arterial oxygen saturation and, based on the tissue parameters previously determined on the basis of the impedance measurement the capillary oxygen saturation is calculated.
- the blood flow and the arterial temperature are determined from the measurement signals of the heat measurement unit 120 and from the data which can be derived from the time-dependent impedance measurement.
- the pulse wave velocity is determined.
- the evaluation unit 140 uses the results of all previously performed calculations to calculate the venous oxygen saturation, and from this further metabolic parameters, in particular the local oxygen consumption and the glucose concentration at the measuring location.
- the calculation results are interpreted by means of a diagnostic unit 150.
- the diagnostic unit 150 is used to evaluate the calculated by the evaluation unit 140 local metabolic parameters.
- the evaluation unit 140 and the diagnostic unit 150 are connected to a graphics unit 160 for displaying the measurement results.
- the data obtained can be stored in a memory unit 170, with simultaneous storage of the date and time of the respective measurement.
- an interface unit 180 is provided which serves to transmit the calculated physiological parameters.
- all data and parameters in particular also the data and parameters stored in the memory unit 170, can be transmitted, for example, to a PC, not shown, of a treating physician. There the data can be analyzed in more detail. In particular, data and parameters recorded with the measuring device 300 over a relatively long period of time can be examined for changes in order to be able to derive conclusions therefrom with regard to the development of an existing disease.
- FIG. 5 schematically shows a further embodiment of the measuring device 300 according to the invention.
- an ECG electrode 9 is attached on the outside of the housing 400. This electrode is touched with the finger of one hand. A finger of the other hand is inserted into a tubular opening 10. Inside the opening 10 are the electrodes 1, 3, the light sources 5, 5 ', the light sensors 6 and the heat sensor 7. Furthermore, inside the tube 10, an inflatable air cushion 11 is arranged, which fixes the finger gently and with a defined Pressure against the sensors presses. Operating buttons of the measuring device 300 and a display for outputting the measurement results are in the. For clarity FIG. 6 omitted.
- the FIG. 6 shows the circuit construction of the impedance measuring unit 100 of the measuring device 300 according to the invention as a block diagram.
- the impedance measuring unit 100 includes a digital signal generator 60, which is supplied with an external clock signal 61.
- the digital signal is converted by means of a digital / analog converter 62 into an analog signal and amplified by means of an amplifier 63.
- a variable frequency alternating current signal is generated, which is supplied via the feed electrode 1 to the body of the examined patient.
- the impedance measurement signal is detected via a measuring electrode 3 and amplified by means of an amplifier 65.
- the amplifier 65 is followed by a variable attenuator 66 and a low-pass filter 67 for the purpose of noise suppression.
- the amplified and filtered analog signal is converted into a digital signal by means of an analog / digital converter 68 and transformed by means of a digital Fourier transformation unit 69.
- the real and imaginary parts of the Fourier transformed measurement signal are stored in registers 70 and 71, respectively.
- the registers 70 and 71 can be interrogated via an interface 72 (eg I 2 C interface). About the interface 72 are the Fourier-transformed digital signals to the evaluation unit 140 of the measuring device 300 according to the invention transmitted.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007042550 | 2007-09-07 | ||
PCT/EP2008/007331 WO2009033625A1 (de) | 2007-09-07 | 2008-09-08 | Medizinische messvorrichtung zur bioelektrischen impedanzmessung |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2203114A1 EP2203114A1 (de) | 2010-07-07 |
EP2203114B1 true EP2203114B1 (de) | 2011-11-16 |
Family
ID=40220165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08801910A Active EP2203114B1 (de) | 2007-09-07 | 2008-09-08 | Medizinische messvorrichtung zur bioelektrischen impedanzmessung |
Country Status (7)
Country | Link |
---|---|
US (1) | US9060700B2 (ko) |
EP (1) | EP2203114B1 (ko) |
JP (2) | JP6125743B2 (ko) |
KR (1) | KR101629974B1 (ko) |
CN (1) | CN101827554B (ko) |
AT (1) | ATE533399T1 (ko) |
WO (1) | WO2009033625A1 (ko) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ113799A0 (en) | 1999-06-22 | 1999-07-15 | University Of Queensland, The | A method and device for measuring lymphoedema |
CA2528303A1 (en) | 2004-11-26 | 2006-05-26 | Z-Tech (Canada) Inc. | Weighted gradient method and system for diagnosing disease |
US9724012B2 (en) | 2005-10-11 | 2017-08-08 | Impedimed Limited | Hydration status monitoring |
EP2020918B1 (en) | 2006-05-30 | 2015-05-20 | Impedimed Limited | Impedance measurements |
WO2008064426A1 (en) | 2006-11-30 | 2008-06-05 | Impedimed Limited | Measurement apparatus |
ES2537077T3 (es) | 2007-03-30 | 2015-06-02 | Impedimed Limited | Protección activa para reducción de carga de señal resistiva y capacitiva con control ajustable de nivel de compensación |
JP5419861B2 (ja) | 2007-04-20 | 2014-02-19 | インぺディメッド リミテッド | インピーダンス測定装置および方法 |
US9615766B2 (en) | 2008-11-28 | 2017-04-11 | Impedimed Limited | Impedance measurement process |
DE102010032531A1 (de) | 2010-07-28 | 2012-02-02 | Ingo Flore | Portable diagnostische Messvorrichtung |
SG10201510693UA (en) * | 2010-12-28 | 2016-01-28 | Sotera Wireless Inc | Body-worn system for continous, noninvasive measurement of cardiac output, stroke volume, cardiac power, and blood pressure |
KR101832264B1 (ko) | 2011-08-25 | 2018-04-13 | 삼성전자주식회사 | 생체 신호를 측정하는 장치 및 방법 |
DE112013000530T5 (de) * | 2012-01-10 | 2014-10-02 | Maxim Integrated Products, Inc. | Plusfrequenz- und Blutsauerstoff-Überwachungesystem |
RU2518134C2 (ru) | 2012-02-24 | 2014-06-10 | Хилби Корпорейшн | Способ определения концентрации глюкозы в крови человека |
EP2656785B9 (en) * | 2012-04-26 | 2019-08-28 | Fresenius Medical Care Deutschland GmbH | Electrodes for a bio-impedance measuring device, and devices used during dialysis |
JP6020082B2 (ja) * | 2012-11-19 | 2016-11-02 | Tdk株式会社 | 生体信号計測装置、生体信号計測方法及び生体信号計測プログラム |
CN103169469B (zh) * | 2013-01-16 | 2016-01-20 | 常州博睿康科技有限公司 | 一种基于高频激励的实时脑电阻抗检测方法 |
DE102013000966A1 (de) * | 2013-01-22 | 2014-07-24 | Zimmer Medizinsysteme Gmbh | Verfahren und Gerät zur kontinuierlichen, nicht invasiven Messung von Gewebetemperaturen in unterschiedlichen Gewebetiefen |
AT514017B1 (de) | 2013-02-22 | 2020-11-15 | Dr Skrabal Falko | Hämodynamisches EKG |
US9833192B2 (en) | 2013-03-15 | 2017-12-05 | Thought Technology Ltd. | Finger mounted physiology sensor |
KR101471598B1 (ko) * | 2013-08-01 | 2014-12-10 | 광주과학기술원 | 압력측정방법 및 압력측정장치 |
TWI476415B (zh) * | 2013-08-16 | 2015-03-11 | Ind Tech Res Inst | 阻抗分析裝置及方法 |
US10478075B2 (en) * | 2013-10-25 | 2019-11-19 | Qualcomm Incorporated | System and method for obtaining bodily function measurements using a mobile device |
TW201529041A (zh) * | 2013-12-11 | 2015-08-01 | Samsung Electronics Co Ltd | 用於提供生物阻抗感應器陣列的方法及系統 |
CN103750837A (zh) * | 2014-01-21 | 2014-04-30 | 广州市康普瑞生营养健康咨询有限公司 | 生物电阻抗测量装置 |
CN105455808A (zh) * | 2014-07-07 | 2016-04-06 | 北京大学深圳研究生院 | 一种用于测量人体体表电特性的电极及测量系统 |
KR102265066B1 (ko) | 2014-07-17 | 2021-06-15 | 삼성전자주식회사 | 생체 임피던스 측정 방법 및 장치 |
DE102014014071A1 (de) * | 2014-09-29 | 2016-03-31 | Trw Automotive Gmbh | Fahrzeugbedienelement sowie Verfahren zur nichtinvasiven Messung von Biomolekülen |
NL2013920B1 (en) * | 2014-12-04 | 2016-08-08 | Mergent B V | Communication device for primates, in particular persons, and method for operating such a device. |
KR102335739B1 (ko) | 2014-12-19 | 2021-12-06 | 삼성전자주식회사 | 비 침습적 혈당 측정 방법 및 이를 위한 장치 |
US9696199B2 (en) * | 2015-02-13 | 2017-07-04 | Taiwan Biophotonic Corporation | Optical sensor |
CN106137191A (zh) * | 2015-04-07 | 2016-11-23 | 联想(北京)有限公司 | 一种电子设备及信息处理方法 |
JP2016220961A (ja) * | 2015-05-29 | 2016-12-28 | 国立大学法人九州大学 | 皮膚抵抗測定装置 |
CN105011946B (zh) * | 2015-07-22 | 2018-05-04 | 通普生物科技(北京)有限公司 | 测量血糖值的方法 |
KR20170020633A (ko) | 2015-08-13 | 2017-02-23 | 성균관대학교산학협력단 | 생체조직 진단 장치, 암 치료 장치 및 암 진단 및 치료 장치 |
US10779765B2 (en) | 2015-09-28 | 2020-09-22 | Aclaris Medical, Llc | Wearable physiologic sensing apparatus |
WO2017079794A1 (en) * | 2015-11-10 | 2017-05-18 | Impedimed Limited | Impedance measurement system |
EP3391036A4 (en) * | 2015-12-18 | 2019-07-31 | Trividia Health, Inc. | IN VITRO SENSOR USING A TRIPOLAR IMPEDANCE MEASUREMENT |
CN105852839B (zh) * | 2016-03-23 | 2018-11-02 | 中山大学 | 一种基于生物电阻抗技术的心率测量方法及装置 |
AT518762B1 (de) * | 2016-05-27 | 2021-06-15 | Leonh Lang | Prüfvorrichtung |
EP3318187A1 (en) * | 2016-11-07 | 2018-05-09 | Nokia Technologies OY | Electrode for physiological measurements |
CN106667498A (zh) * | 2017-03-03 | 2017-05-17 | 蔡曜聪 | 生理检测装置 |
WO2018157369A1 (zh) * | 2017-03-03 | 2018-09-07 | 蔡曜聪 | 生理检测装置 |
US11109797B2 (en) | 2017-09-05 | 2021-09-07 | Apple Inc. | Portable electronic device having an integrated bio-sensor |
KR102500766B1 (ko) | 2017-12-29 | 2023-02-17 | 삼성전자주식회사 | 생체 신호 측정 장치 및 그의 동작 방법 |
CN108635186A (zh) * | 2018-05-07 | 2018-10-12 | 利辛县众善医药科技有限公司 | 一种自动调节医疗护理用按摩装置 |
US11488361B1 (en) * | 2019-02-15 | 2022-11-01 | Meta Platforms Technologies, Llc | Systems and methods for calibrating wearables based on impedance levels of users' skin surfaces |
KR20200120398A (ko) | 2019-04-12 | 2020-10-21 | 삼성전자주식회사 | 체내 물질 성분 분석 장치 및 방법과, 임피던스 측정 장치 |
WO2020237652A1 (zh) * | 2019-05-31 | 2020-12-03 | 麦层移动健康管理有限公司 | 一种用于提取生物组织特征信息的非侵入性方法及其系统 |
JP6876258B2 (ja) * | 2019-11-05 | 2021-05-26 | 永健生技醫療器材有限公司eTouch Medical Inc. | 非侵襲血糖値測定機システム、及びその方法 |
KR20210092577A (ko) | 2020-01-16 | 2021-07-26 | 삼성전자주식회사 | 성분 분석 장치 및 방법과 임피던스 측정 장치 |
KR20220050676A (ko) * | 2020-10-16 | 2022-04-25 | 삼성전자주식회사 | 임피던스 측정 장치 |
US20220133999A1 (en) * | 2020-10-30 | 2022-05-05 | Medtronic, Inc. | Monitoring of physiological parameters with impedance measurement |
KR102644079B1 (ko) | 2021-09-24 | 2024-03-07 | 주식회사 휘라포토닉스 | 광학 혈당 센서용 광도파로 모듈 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3229686A (en) * | 1963-07-05 | 1966-01-18 | Physio Control Company Inc | Blood pressure and heart beat pulse rate measuring system |
US3805795A (en) | 1972-03-17 | 1974-04-23 | Medtronic Inc | Automatic cardioverting circuit |
US3958560A (en) | 1974-11-25 | 1976-05-25 | Wayne Front March | Non-invasive automatic glucose sensor system |
US4938218A (en) * | 1983-08-30 | 1990-07-03 | Nellcor Incorporated | Perinatal pulse oximetry sensor |
US4911167A (en) * | 1985-06-07 | 1990-03-27 | Nellcor Incorporated | Method and apparatus for detecting optical pulses |
DE3533912A1 (de) * | 1985-09-23 | 1987-04-02 | Schmid Walter | Blutdruckmessgeraet |
US5259381A (en) * | 1986-08-18 | 1993-11-09 | Physio-Control Corporation | Apparatus for the automatic calibration of signals employed in oximetry |
US4960126A (en) * | 1988-01-15 | 1990-10-02 | Criticare Systems, Inc. | ECG synchronized pulse oximeter |
US4928014A (en) * | 1988-10-03 | 1990-05-22 | Futrex, Inc. | Near-infrared apparatus and method for determining percent fat in a body |
US5237178A (en) * | 1990-06-27 | 1993-08-17 | Rosenthal Robert D | Non-invasive near-infrared quantitative measurement instrument |
US4934382A (en) * | 1989-07-03 | 1990-06-19 | Barone Jr Richard J | Protective sheath with manipulation tabs |
GB9011887D0 (en) * | 1990-05-26 | 1990-07-18 | Le Fit Ltd | Pulse responsive device |
EP0467853B1 (de) * | 1990-07-18 | 1996-01-10 | AVL Medical Instruments AG | Einrichtung und Verfahren zur Blutdruckmessung |
DE4029637C1 (ko) * | 1990-09-19 | 1992-02-20 | Messerschmitt-Boelkow-Blohm Gmbh, 8012 Ottobrunn, De | |
US6128518A (en) * | 1990-10-04 | 2000-10-03 | Microcor, Inc. | System and method for in-vivo hematocrit measurement using impedance and pressure plethysmography |
US5191891A (en) * | 1991-09-10 | 1993-03-09 | Ralin, Inc. | Portable ECG monitor/recorder |
US5353790A (en) | 1992-01-17 | 1994-10-11 | Board Of Regents, The University Of Texas System | Method and apparatus for optical measurement of bilirubin in tissue |
IL107396A (en) * | 1992-11-09 | 1997-02-18 | Boehringer Mannheim Gmbh | Method and apparatus for analytical determination of glucose in a biological matrix |
US5515847A (en) * | 1993-01-28 | 1996-05-14 | Optiscan, Inc. | Self-emission noninvasive infrared spectrophotometer |
DE4329898A1 (de) * | 1993-09-04 | 1995-04-06 | Marcus Dr Besson | Kabelloses medizinisches Diagnose- und Überwachungsgerät |
DE4342105A1 (de) * | 1993-12-12 | 1995-06-14 | Cho Ok Kyung | Verfahren und Vorrichtung zur noninvasiven Bestimmung der Konzentration der Glucose in Teilen des menschlichen Körpers, inbesondere im menschlichen Blut, unter Durchführung höchstgenauer Temperaturmessungen des menschlichen Körpers |
DE4423663A1 (de) * | 1994-07-06 | 1996-01-11 | Med Science Gmbh | Verfahren und Vorrichtung zur Erfassung von Wärmewechselwirkungen zwischen dem menschlichen Körper und der erfindungsgemäßen Vorrichtung und deren Korrelation mit der Glucosekonzentration im menschlichen Blut |
FI943283A (fi) | 1994-07-11 | 1996-01-12 | Polar Electro Oy | Tiedonsyöttölaite |
US5752512A (en) * | 1995-05-10 | 1998-05-19 | Massachusetts Institute Of Technology | Apparatus and method for non-invasive blood analyte measurement |
DE19519125A1 (de) | 1995-05-17 | 1996-11-21 | Victor Victorovic Vetckanov | Manuell zu betätigendes Eingabegerät |
US5682902A (en) * | 1995-10-16 | 1997-11-04 | Hewlett-Packard Company | ECG pace pulse detection and processing |
US5743856A (en) * | 1995-11-06 | 1998-04-28 | Colin Corporation | Apparatus for measuring pulse-wave propagation velocity |
US6041247A (en) * | 1995-11-29 | 2000-03-21 | Instrumentarium Corp | Non-invasive optical measuring sensor and measuring method |
US6159147A (en) * | 1997-02-28 | 2000-12-12 | Qrs Diagnostics, Llc | Personal computer card for collection of real-time biological data |
DE69940053D1 (de) * | 1998-02-05 | 2009-01-22 | Hema Metrics Inc | Verfahren und vorrichtung zur nicht-invasiven beobachtung von blutbestandteilen |
AU4214199A (en) | 1998-06-03 | 1999-12-20 | Masimo Corporation | Stereo pulse oximeter |
DE29811049U1 (de) | 1998-06-22 | 1998-12-24 | Targis Healthcare Communicatio | Mobiles Meßgerät, insbesondere Blutzuckermeßgerät |
WO2000001295A1 (en) * | 1998-07-07 | 2000-01-13 | Lightouch Medical, Inc. | Tissue modulation process for quantitative noninvasive in vivo spectroscopic analysis of tissues |
JP2000083933A (ja) * | 1998-07-17 | 2000-03-28 | Nippon Koden Corp | 生体組織中吸光物質濃度測定装置 |
JP3840816B2 (ja) * | 1998-10-02 | 2006-11-01 | オムロンヘルスケア株式会社 | 血圧監視装置 |
KR100321261B1 (ko) * | 1999-01-11 | 2002-01-19 | 차기철 | 심박출량과 심전도를 모니터링하기 위한 전극 설치 방법 및 이를 이용한 장치 |
US6331162B1 (en) * | 1999-02-01 | 2001-12-18 | Gary F. Mitchell | Pulse wave velocity measuring device |
DE19922772A1 (de) | 1999-05-18 | 2001-02-08 | Phiscience Gmbh Entwicklung Vo | Vorrichtung zur Bestimmung verschiedener Druchblutungszustände und der Sauerstoffsättigung in blutführendem Gewebe |
WO2001028416A1 (en) * | 1999-09-24 | 2001-04-26 | Healthetech, Inc. | Physiological monitor and associated computation, display and communication unit |
NZ518142A (en) * | 1999-10-07 | 2003-11-28 | Alexander K | Optical determination of blood characteristics accounting for heart/limb relative height |
DE19962700A1 (de) * | 1999-12-23 | 2001-06-28 | Lre Technology Partner Gmbh | Blutdruckmeßgerät |
JP2001187029A (ja) * | 1999-12-28 | 2001-07-10 | Nippon Seimitsu Sokki Kk | 体脂肪率測定機能を備えた血圧計 |
AU2001229916A1 (en) * | 2000-01-27 | 2001-08-07 | National Research Council Of Canada | Visible-near infrared spectroscopy in burn injury assessment |
DE10009882A1 (de) | 2000-03-01 | 2001-10-11 | Dietmar W Klaudtky | Mobiles Telekommunikations-Endgerät, insbesondere Mobiltelefon |
US6714814B2 (en) * | 2000-03-30 | 2004-03-30 | Tanita Corporation | Bioelectrical impedance measuring apparatus |
US6616613B1 (en) * | 2000-04-27 | 2003-09-09 | Vitalsines International, Inc. | Physiological signal monitoring system |
US6819950B2 (en) | 2000-10-06 | 2004-11-16 | Alexander K. Mills | Method for noninvasive continuous determination of physiologic characteristics |
JP2004528935A (ja) * | 2001-06-13 | 2004-09-24 | シーケーエム ダイアグノスティックス,インコーポレーテッド | 組織の非侵襲的検出方法及び検出装置 |
DE10136355A1 (de) * | 2001-07-26 | 2003-02-13 | Niels Rahe-Meyer | Vorrichtung zur Untersuchung und Überwachung von Vitalparamentern des Körpers |
IL145445A (en) | 2001-09-13 | 2006-12-31 | Conmed Corp | A method for signal processing and a device for improving signal for noise |
GB2381530A (en) * | 2001-11-01 | 2003-05-07 | Oxonica Ltd | Water-soluble particles of luminescent materials and their use in Biotagging |
DE60207183T2 (de) | 2001-12-10 | 2006-08-10 | Kabushiki Gaisha K-And-S | Vorrichtung zur Beobachtung biologischer Daten |
US20030109901A1 (en) * | 2001-12-11 | 2003-06-12 | Wilson Greatbatch | Photonic pacemaker-cardiac monitor |
KR100459903B1 (ko) * | 2002-07-25 | 2004-12-03 | 삼성전자주식회사 | 피부의 국부적인 영역의 임피던스를 측정하는 측정 시스템및 이에 이용되는 임피던스 측정 전극 |
US6763256B2 (en) * | 2002-08-16 | 2004-07-13 | Optical Sensors, Inc. | Pulse oximeter |
US6879850B2 (en) * | 2002-08-16 | 2005-04-12 | Optical Sensors Incorporated | Pulse oximeter with motion detection |
US7783345B2 (en) * | 2002-10-07 | 2010-08-24 | Cnsystems Medizintechnik Gmbh | Impedance-based measuring method for hemodynamic parameters |
KR20040032451A (ko) | 2002-10-09 | 2004-04-17 | 삼성전자주식회사 | 생체신호 기반의 건강 관리 기능을 갖는 모바일 기기 및이를 이용한 건강 관리 방법 |
US8157731B2 (en) * | 2002-10-09 | 2012-04-17 | Bodymedia, Inc. | Method and apparatus for auto journaling of continuous or discrete body states utilizing physiological and/or contextual parameters |
US8672852B2 (en) * | 2002-12-13 | 2014-03-18 | Intercure Ltd. | Apparatus and method for beneficial modification of biorhythmic activity |
US20050148882A1 (en) * | 2004-01-06 | 2005-07-07 | Triage Wireless, Incc. | Vital signs monitor used for conditioning a patient's response |
US6968221B2 (en) * | 2003-03-14 | 2005-11-22 | Futrex, Inc. | Low-cost method and apparatus for non-invasively measuring blood glucose levels |
JP3566276B1 (ja) * | 2003-05-07 | 2004-09-15 | 株式会社日立製作所 | 血糖値測定装置 |
US6993372B2 (en) * | 2003-06-03 | 2006-01-31 | Orsense Ltd. | Method and system for use in non-invasive optical measurements of blood parameters |
TWI292276B (en) * | 2003-06-17 | 2008-01-01 | Benq Corp | A mobile telephone with the function of measuring fat |
JP3566277B1 (ja) | 2003-06-23 | 2004-09-15 | 株式会社日立製作所 | 血糖値測定装置 |
US20050078533A1 (en) * | 2003-10-10 | 2005-04-14 | Andrey Vyshedskiy | Physiological data recording apparatus for single handed application |
GB2408209A (en) | 2003-11-18 | 2005-05-25 | Qinetiq Ltd | Flexible medical light source |
US7305262B2 (en) * | 2003-12-11 | 2007-12-04 | Ge Medical Systems Information Technologies, Inc. | Apparatus and method for acquiring oximetry and electrocardiogram signals |
WO2005077260A1 (en) * | 2004-02-12 | 2005-08-25 | Biopeak Corporation | Non-invasive method and apparatus for determining a physiological parameter |
US20060009697A1 (en) * | 2004-04-07 | 2006-01-12 | Triage Wireless, Inc. | Wireless, internet-based system for measuring vital signs from a plurality of patients in a hospital or medical clinic |
TWM271207U (en) * | 2004-12-20 | 2005-07-21 | Sheng-Chin Hou | Input device |
DE102005013429A1 (de) * | 2005-03-21 | 2006-09-28 | Flore, Ingo, Dr. | Mobiles Diagnosegerät |
US9924886B2 (en) * | 2005-08-09 | 2018-03-27 | Ingo Flore | Medical measuring device |
DE102005038147A1 (de) * | 2005-08-12 | 2007-02-22 | Dräger Medical AG & Co. KG | Kombinationssensor für die Erfassung physiologischer Messgrößen auf der Haut eines Patienten |
JP2007105329A (ja) * | 2005-10-14 | 2007-04-26 | Hitachi Ltd | 血糖値測定装置及び代謝量測定装置 |
US7539532B2 (en) * | 2006-05-12 | 2009-05-26 | Bao Tran | Cuffless blood pressure monitoring appliance |
US9603521B2 (en) * | 2006-11-23 | 2017-03-28 | Ingo Flore | Medical measuring device |
US8157730B2 (en) | 2006-12-19 | 2012-04-17 | Valencell, Inc. | Physiological and environmental monitoring systems and methods |
CN104478093B (zh) * | 2007-04-12 | 2016-06-01 | 诺维信生物股份有限公司 | 废水处理 |
DE102009011381A1 (de) * | 2009-03-05 | 2010-09-09 | Flore, Ingo, Dr. | Diagnostische Messvorrichtung |
-
2008
- 2008-09-08 JP JP2010523330A patent/JP6125743B2/ja active Active
- 2008-09-08 KR KR1020107007103A patent/KR101629974B1/ko active IP Right Grant
- 2008-09-08 WO PCT/EP2008/007331 patent/WO2009033625A1/de active Application Filing
- 2008-09-08 CN CN200880112146.8A patent/CN101827554B/zh active Active
- 2008-09-08 US US12/733,551 patent/US9060700B2/en active Active
- 2008-09-08 AT AT08801910T patent/ATE533399T1/de active
- 2008-09-08 EP EP08801910A patent/EP2203114B1/de active Active
-
2017
- 2017-02-02 JP JP2017017978A patent/JP2017094192A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6125743B2 (ja) | 2017-05-10 |
JP2010537752A (ja) | 2010-12-09 |
CN101827554B (zh) | 2014-07-16 |
KR20100061824A (ko) | 2010-06-09 |
ATE533399T1 (de) | 2011-12-15 |
JP2017094192A (ja) | 2017-06-01 |
CN101827554A (zh) | 2010-09-08 |
US20100234701A1 (en) | 2010-09-16 |
EP2203114A1 (de) | 2010-07-07 |
KR101629974B1 (ko) | 2016-06-14 |
WO2009033625A1 (de) | 2009-03-19 |
US9060700B2 (en) | 2015-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2203114B1 (de) | Medizinische messvorrichtung zur bioelektrischen impedanzmessung | |
EP2096989B1 (de) | Medizinische messvorrichtung | |
EP2203113B1 (de) | Diagnostische sensoreinheit | |
EP2403398B1 (de) | Diagnostische messvorrichtung | |
EP1931239B1 (de) | Medizinische messvorrichtung | |
EP2096984B1 (de) | Medizinische messvorrichtung | |
DE69727243T2 (de) | Sensor zur an die bewegung angepasste nicht-invasiven optischen blutanalyse | |
Ferrari et al. | Near infrared brain and muscle oximetry: from the discovery to current applications | |
DE102006055691A1 (de) | Medizinische Messvorrichtung | |
DE102005057757A1 (de) | Integrale Vorrichtung zur Bestimmung physiologischer Signale | |
Tayel et al. | Poincaré plot for heart rate variability | |
DE112013005657T5 (de) | Oxymetriesensoranordnung und Vorgehensweise zum Abtasten einer Blutsauerstoffkonzentration | |
DE102016006196A1 (de) | Innovatives verfahren und multisensor-plattform zum nichtinvasiven monitoring von physiologischen parameter und blutinhaltstoffe sowie frühdiagnose der pathologischen änderungen und gesundheits-management und ihre anwendung mit smartphone | |
DE102006051561A1 (de) | Anzeigemittel für Vitalparameter | |
EP2609854B1 (de) | Bewegungskorreliertes Verfahren und opto-elektronische Vorrichtung zur nichtinvasiven Bestimmung der dermalvenösen Sauerstoffversorgung peripherer Beingebiete | |
US20190328241A1 (en) | Determining changes to autoregulation | |
JP2000262480A (ja) | 生体恒常性維持評価装置 | |
DE102006026126A1 (de) | Verfahren und Multisensor zur nichtinvasiven Überwachung der fraktionellen Sauerstoffsättigung und Detektion pathologischer Veränderungen im Herzkreislaufsystem | |
DE102015015113A1 (de) | Verfahren und multisensor zum nichtinvasiven monitoring von physiologischen parameter und blutinhaltstoffe sowie frühdiagnose der pathologischen änderungen mittels fuzzy logik datafusion für decision making und consulting bei internet of things | |
Jagelka et al. | Wearable healthcare electronics for 24-7 monitoring with focus on user comfort | |
Mirescu et al. | Challenges in implementing heart rate variability testing in a family medicine practice: Strengths pitfalls and caveats | |
Lin et al. | Estimation of Blood Glucose Level of Human by Measuring Key Parameters in Electrocardiogram | |
Shi | Photoplethysmography in noninvasive cardiovascular assessment | |
DE102014019658B4 (de) | Sauerstoffsättigungsdetektionsvorrichtung zur Detektion und Signalisierung der arteriellen Sauerstoffsättigung und Verfahren zur Steigerung der körperlichen Leistungsfähigkeit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100407 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 502008005612 Country of ref document: DE Effective date: 20120216 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20111116 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20111116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120216 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120316 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120316 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120217 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120216 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20120817 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 502008005612 Country of ref document: DE Effective date: 20120817 |
|
BERE | Be: lapsed |
Owner name: FLORE, INGO Effective date: 20120930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120227 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120930 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120930 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080908 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 533399 Country of ref document: AT Kind code of ref document: T Effective date: 20130908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130908 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230428 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230920 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230928 Year of fee payment: 16 Ref country code: DE Payment date: 20230920 Year of fee payment: 16 |